Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors
Butrynski JE
G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of glucocorticoid receptor target genes
Formula: C18H21FN2O
Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents
ML-329 - CAS# 19992-50-8 Catalog No.:M6543-2 Evidence that PERK is implicatedML 329, CAS No. 19992 50 8, is an inhibitor of the microphthalmia associated transcription factor (MITF) pathway with an IC50 value of 1. 2 M for promoter activity of the MITF target gene TRPM 1. ML 329 showed specific activity against the MITF dependent cells, primary melanocytes but no effect on the viability in A375 cells. ML 329 reduced the expression of multiple MITF target genes, including pigment related genes and the cell cycle regulator CDK2.